Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyHealth New England TTVR Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHealth-New-EnglandPolicy UM1003POL

    Transcatheter Tricuspid Valve Interventions Medical Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM1003POL alerts

    Get alerted when Policy UM1003POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity determinations for transcatheter tricuspid valve repair, replacement, and caval valve implantation for Health New England Commercial, Medicare Advantage, and Medicaid members.

    Policy Summary
    PayerHealth-New-England
    PolicyTranscatheter Tricuspid Valve Interventions Medical Policy
    Policy CodePolicy UM1003POL
    Change TypeMaterial coverage update
    Effective DateSeptember 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for the listed transcatheter tricuspid valve repair and replacement procedures.
    SourceLink
    POLICY UPDATE CHANGES

    Medicare coverage for transcatheter tricuspid valve replacement and transcatheter edge-to-edge repair now uses adopted InterQual criteria together with the applicable Medicare National Coverage Determinations.

    Commercial and Medicaid criteria were added for transcatheter tricuspid valve replacement or repair when severe symptomatic tricuspid regurgitation persists despite optimal medical therapy and the heart team determines that open-heart surgery presents high risk.

    Transcatheter edge-to-edge repair for tricuspid regurgitation is addressed through the applicable Medicare National Coverage Determination and adopted criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Lines of business addressed
    2Commercial/Medicaid medical-necessity conditions
    2Medicare NCDs referenced
    CAVIExperimental and investigational
    6CPT Category III codes listed

    Medical Necessity and Coverage Criteria

    Commercial and Medicaid TTVR or T-TEER

    For Commercial and Medicaid lines of business, TTVR or T-TEER may be considered medically necessary when all of the following are met:

    Commercial and Medicaid medical necessity

    • Clinical severity and treatment failure

      • Symptomatic severe tricuspid regurgitation despite optimal medical therapy.Severe symptomatic TR despite OMT
    • Heart-team assessment

      • Tricuspid valve replacement or repair is considered appropriate based on evaluation by a heart team consisting of a cardiac surgeon, interventional cardiologist, and cardiologist.
      • The heart team considers the member to be at high risk for clinically indicated open-heart surgical intervention for severe tricuspid regurgitation.High risk for open-heart surgery

    Medicare TTVR and T-TEER

    For Medicare, coverage is evaluated using the adopted InterQual criteria and applicable Medicare National Coverage Determination requirements.

    Medicare TTVR

    • Meet the adopted InterQual criteria for Transcatheter Tricuspid Valve Replacement and the applicable Medicare NCD requirements, including NCD 20.37 and its transcatheter tricuspid valve replacement coverage-with-evidence-development study.Applicable InterQual and NCD 20.37 requirements

      The detailed InterQual criteria are not reproduced in this policy.

    Medicare T-TEER

    • Meet the adopted InterQual criteria for Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation and the applicable Medicare NCD requirements, including NCD 20.38 and its transcatheter edge-to-edge repair coverage-with-evidence-development study.Applicable InterQual and NCD 20.38 requirements

      The detailed InterQual criteria are not reproduced in this policy.

    Transcatheter Caval Valve Implantation

    Transcatheter caval valve implantation is not medically necessary under this policy.

    CAVI investigational status

    • Transcatheter caval valve implantation is considered experimental and investigational for all lines of business due to insufficient evidence of efficacy.

      Applies to all lines of business.

    TTVR or T-TEER for indications other than those meeting the applicable coverage criteria is considered not medically necessary.

    For Medicare members, TTVR or T-TEER for indications other than those addressed by the adopted InterQual criteria and applicable Medicare NCD requirements is considered not medically necessary.

    Procedure Coding Guidance

    Experimental and investigational proceduresCPTExperimental
    0545TTranscatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach.
    0805TTranscatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); percutaneous femoral vein approach.
    0806TTranscatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); open femoral vein approach.
    Prior authorization proceduresCPT
    0569TTranscatheter tricuspid valve repair, percutaneous approach; initial prosthesis.
    0570TTranscatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure).
    0646TTranscatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for TTVR and T-TEER

    Prior authorization is required before performing covered transcatheter tricuspid valve repair or replacement procedures, including T-TEER and TTVR. Apply the applicable medical-necessity criteria by line of business: Commercial and Medicaid criteria are specified in the policy, while Medicare uses adopted InterQual criteria and applicable CMS NCD requirements.

    • PA required: CPT 0569T and 0570T for percutaneous transcatheter tricuspid valve repair.
    • PA required: CPT 0646T for percutaneous transcatheter tricuspid valve implantation/replacement (TTVR).
    • CPT 0545T is designated experimental and investigational; do not treat it as a covered TTVR or T-TEER service without applicable review.
    Documentation Required

    Medical-Necessity Documentation

    Submit clinical evidence demonstrating that the requested TTVR or T-TEER is medically necessary. For Commercial and Medicaid requests, document severe symptomatic tricuspid regurgitation despite optimal medical therapy and the heart team’s determination that the member is at high risk for clinically indicated open-heart surgery.

    Clinical Background

    The tricuspid valve directs blood flow from the right atrium to the right ventricle and prevents backflow. Tricuspid regurgitation occurs when the valve allows blood to flow backward, while tricuspid stenosis narrows the valve and restricts forward flow. These conditions may be congenital or acquired, and advanced disease can cause symptomatic right-sided heart failure.

    Terms and Abbreviations

    Optimal medical therapy (OMT)
    DiureticsUse when severe tricuspid regurgitation is accompanied by heart-failure signs.
    Underlying cause of right-sided heart failureFor right-sided heart failure attributable to severe secondary tricuspid regurgitation, treat the primary cause when applicable.
    Pulmonary vasodilatorsMay be used to reduce elevated pulmonary artery pressures.
    Heart-failure therapyUse guideline-directed medical therapy for heart failure with reduced left ventricular ejection fraction when applicable.
    Atrial fibrillationUse rhythm control when applicable.
    Transcatheter caval valve implantation (CAVI)
    Policy Summary
    PayerHealth-New-England
    PolicyTranscatheter Tricuspid Valve Interventions Medical Policy
    Policy CodePolicy UM1003POL
    Change TypeMaterial coverage update
    Effective DateSeptember 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for the listed transcatheter tricuspid valve repair and replacement procedures.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaProcedure Coding GuidanceAuthorization and Documentation RequirementsClinical BackgroundTerms and Abbreviations
    • Document symptomatic severe tricuspid regurgitation despite optimal medical therapy.
    • Document heart-team evaluation by a cardiac surgeon, interventional cardiologist, and cardiologist supporting valve repair or replacement.
    • Document the heart team’s determination that the member is at high risk for clinically indicated open-heart surgical intervention.
    Documentation Required

    Medicare Criteria Documentation

    For Medicare requests, provide documentation supporting HNE’s adopted InterQual criteria and the applicable Medicare National Coverage Determination requirements for the requested procedure.

    • For TTVR, reference InterQual criteria and Medicare NCD 20.37, including applicable coverage-with-evidence-development study requirements.
    • For T-TEER, reference InterQual criteria and Medicare NCD 20.38, including applicable coverage-with-evidence-development study requirements.
    • Include the clinical records and procedure-specific evidence needed to demonstrate compliance with the applicable criteria.
    Documentation Required

    Document Optimal Medical Therapy

    Document the member’s optimal medical therapy before requesting TTVR or T-TEER. The record should identify treatment directed at severe tricuspid regurgitation, heart-failure signs, and any underlying cause of right-sided heart failure.

    • Document diuretic use when severe tricuspid regurgitation is accompanied by signs of heart failure.
    • For signs and symptoms of right-sided heart failure attributable to severe secondary tricuspid regurgitation, document treatment of the primary cause, such as pulmonary vasodilators for elevated pulmonary artery pressures.
    • When applicable, document guideline-directed heart-failure therapy for reduced left ventricular ejection fraction or rhythm control of atrial fibrillation.
    Denial Risk

    Indications Outside Policy Criteria

    Requests for TTVR or T-TEER that do not meet the applicable policy criteria are considered not medically necessary. This includes indications outside the specified Commercial, Medicaid, or Medicare criteria.

    • For Commercial and Medicaid, all criteria must be satisfied, including severe symptomatic tricuspid regurgitation despite optimal medical therapy and high surgical risk determined by the heart team.
    • For Medicare, the request must satisfy the adopted InterQual criteria and applicable NCD requirements.
    • Do not approve TTVR or T-TEER for indications that fall outside the applicable coverage criteria.
    Denial Risk

    CAVI Is Experimental and Investigational

    Caval valve implantation (CAVI) is considered experimental and investigational for all lines of business because of insufficient evidence of efficacy. The related CAVI codes are not covered under this policy.

    • CPT 0805T: transcatheter superior and inferior vena cava prosthetic valve implantation, percutaneous femoral vein approach — experimental and investigational.
    • CPT 0806T: transcatheter superior and inferior vena cava prosthetic valve implantation, open femoral vein approach — experimental and investigational.
    Documentation Required

    Insufficient Clinical Documentation

    The treating physician or primary care provider must submit clinical evidence showing that the patient meets the applicable treatment criteria. Without sufficient documentation and information, HNE cannot properly review the prior authorization request.

    • Include relevant clinical records, diagnostic findings, treatment history, and provider assessments supporting the requested procedure.
    • Ensure documentation addresses severe symptomatic tricuspid regurgitation, optimal medical therapy, heart-team evaluation, and surgical-risk determination when applicable.
    • Requests lacking evidence supporting the applicable criteria may be delayed, denied, or unable to be properly reviewed.
    ApproachInvestigational technique proposed to relieve symptoms of severe tricuspid regurgitation without repairing or replacing the tricuspid valve.
    Inferior vena cavaImplants a prosthetic valve in the inferior vena cava.
    Superior vena cavaMay also implant a second prosthetic valve in the superior vena cava.
    PurposeRedirects regurgitant blood flow from the failing tricuspid valve.
    Coverage statusConsidered experimental and investigational for all lines of business because of insufficient evidence of efficacy.
    TTVR
    Full termTranscatheter tricuspid valve replacement.
    Procedure typeA transcatheter replacement of the tricuspid valve with a prosthetic valve.
    Commercial and Medicaid criteriaMay be medically necessary for symptomatic severe tricuspid regurgitation despite optimal medical therapy when a heart team considers replacement appropriate and the member is at high risk for clinically indicated open-heart surgery.
    Medicare criteriaRequires the adopted InterQual criteria and applicable Medicare National Coverage Determination requirements, including NCD 20.37.
    T-TEER
    Full termTranscatheter edge-to-edge repair for tricuspid valve regurgitation.
    Procedure typeA transcatheter repair of the tricuspid valve using an edge-to-edge technique.
    Commercial and Medicaid criteriaMay be medically necessary for symptomatic severe tricuspid regurgitation despite optimal medical therapy when a heart team considers repair appropriate and the member is at high risk for clinically indicated open-heart surgery.
    Medicare criteriaRequires the adopted InterQual criteria and applicable Medicare National Coverage Determination requirements, including NCD 20.38.